Ella Hohmann, MS

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.

Alyson Moadel-Robblee, PhD, outlines how the BOLD Program proactively supports cancer caregivers through community-based care.

Alyson Moadel-Robblee, PhD, provides a closer look at how families, especially children, experience a breast cancer diagnosis and why transparency and inclusion are key to healthy coping.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

Five vaccines in development for HIV, tuberculosis, cancer, influenza, and coronaviruses could transform global health.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

Douglas Marks, MD, discusses how diet, exercise, and alcohol reduction can meaningfully lower breast cancer risk

With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.

Shawn Davis, MD, explains why shifting from BMI to adiposity-based care could transform how health systems allocate resources and reduce obesity-driven hospital costs.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

FDA approves Eli Lilly's orforglipron (Foundayo), the first GLP-1 obesity pill with no food or water restrictions.

Novo Nordisk launches a Wegovy subscription program to reduce costs, expand access, and improve long-term adherence.

Soficabtagene geleucel is the first CAR T-cell therapy designed specifically to target T-cell malignancies.

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive breast cancer, with manageable safety and consistent benefits across high-risk subgroups.

The FDA approved higher-dose semaglutide 7.2 mg (Wegovy HD), marking the fourth drug approved under the Commissioner's National Priority Voucher pilot program.

Women aged 35-60 years face higher cancer mortality than men in every generation since the 1930s due to breast and reproductive cancers.

Rural US patients with breast cancer face higher advanced-stage diagnoses, with Black, Hispanic, uninsured patients and those in Southern regions at greatest risk.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

Reproductive health conditions raise child desire but lower pregnancy intentions, spotlighting infertility gaps in women’s health and urging proactive counseling and coverage reform.

Risk-based mammography tailors screening to breast cancer risk, reducing false positives and preventing more deaths than age-based screening.

Sequencing CDK4/6i to the second line rather than the first appears to produce equivalent survival for most patients with meaningfully less treatment burden.

A study of 1.5 million patients suggests that ACA Medicaid expansion reduces breast cancer deaths, especially advanced cases—yet racial and income gaps persist.

While clinicians prioritize rapid regrowth, patients with alopecia areata prioritize safety and shared decision-making.